Haematoma attenuation on non-contrast CT and blood-count inflammatory ratios in spontaneous intracerebral haemorrhage: A systematic review of prognostic studies

When a blood vessel bursts inside the brain, the resulting injury is a race against time. This event, known as a spontaneous intracerebral hemorrhage, is a severe type of stroke that strikes with little warning. While it accounts for a smaller fraction of all strokes compared to blocked vessels, it is far more deadly, often leaving survivors with lasting disability or claiming their lives within weeks. Doctors have long relied on standard scoring systems to judge how severe an injury is when a patient first arrives, but these scores have a blind spot. They look at the patient's condition at a single moment and cannot easily predict the two hidden processes that determine whether a patient will survive the next few days: whether the clot of blood will continue to grow, and how violently the body's immune system will react to the trauma.

To understand the future of a patient, researchers must look at two different clues that are already available in almost every emergency room. The first clue comes from a standard brain scan called a non-contrast computed tomography, or CT. This image shows the blood clot as a bright white shape. Within that shape, areas that appear darker than the rest suggest that the clot is unstable and fresh blood is still seeping in. The second clue comes from a routine blood test that counts the different types of cells flowing through the veins. Specifically, doctors can look at the ratio of white blood cells that fight infection against those that regulate the immune system. These numbers change as the body reacts to the injury, offering a window into the internal storm that follows the bleed.

A team of researchers set out to bring these two separate worlds together. They conducted a systematic review, a rigorous method of gathering and analyzing all the high-quality studies published on this topic up to a specific date. They searched through thousands of records from major medical databases, looking for studies that followed at least fifty adult patients with this type of brain bleed. Their goal was to determine if the darkness seen on the brain scan and the ratios found in the blood test could predict the patient's fate, and if these two types of information offered different kinds of warnings. After filtering out studies that were too small, poorly designed, or did not measure the right things, they assembled a final group of twenty studies involving more than ten thousand patients from countries including China, the United States, and South Korea.

The review found that the two clues tell different parts of the story. The darkness seen on the brain scan, known as low attenuation, proved to be a strong signal that the blood clot was likely to expand. When researchers looked at the scans, they found that patients with these darker spots inside their clots were significantly more likely to experience the bleed growing larger in the hours after admission. This relationship held true whether the doctors were simply looking at the image or measuring the exact density of the blood. The evidence for this link was considered moderately certain, meaning the connection is real and reliable, though more research is always welcome. This suggests that the scan is best used to predict the physical growth of the injury.

The blood tests, however, pointed toward a different outcome. The researchers focused on the ratio of neutrophils, a type of white blood cell that rushes to the scene of an injury, to lymphocytes, which help regulate the response. A higher ratio of these cells was consistently linked to a worse final outcome, including a higher risk of death and a lower chance of regaining independence. This association was found in patients who were treated surgically and in those who were critically ill. The evidence here was rated as low certainty, meaning the trend is clear but the exact strength of the link is still being refined. The blood ratios seemed to reflect the body's systemic reaction to the trauma, predicting how well a patient would recover over time rather than just whether the clot would grow.

Another ratio, comparing lymphocytes to monocytes, showed a more complex pattern. A lower ratio was associated with early neurological decline, but the relationship was not a simple straight line. In one large study, the risk of a poor outcome was highest for patients with the very lowest ratios, but also rose again for those with the highest ratios, forming a U-shaped curve. This suggests that both an overactive and an underactive immune response could be dangerous. The researchers also looked at the size of platelets, the cells that help blood clot, but found only one study that met their strict criteria. That single study found no link between platelet size and the patient's prognosis, leaving the role of this marker uncertain.

The most promising idea explored was whether combining the scan and the blood test could create a super-predictor. One study created a model that mixed the patient's level of consciousness, the blood ratios, and the visual signs on the scan. This combined model performed better than any single factor alone, accurately distinguishing between patients who would survive and those who would not. However, this model has only been tested in one specific group of patients and has not been repeated in other settings. The researchers caution that while the idea is exciting, it remains a hypothesis that needs to be proven in diverse populations before it can be used to guide treatment.

The review concludes that these markers are complementary tools that illuminate different aspects of the injury. The scan reveals the physical state of the clot, warning doctors if the bleeding is likely to worsen immediately. The blood ratios reveal the body's inflammatory response, hinting at the risk of complications and long-term recovery. Currently, no study has shown that acting on these specific numbers changes the outcome for a patient, so they serve as guides for observation rather than triggers for new treatments. The authors emphasize that future research needs to measure both the scan and the blood ratios in the same patients at the same time, using standardized methods, to fully understand how these two forces interact. Until then, these findings offer a clearer picture of the hidden battles happening inside the brain, helping doctors see the risks that standard scores might miss.